A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia
Status:
Terminated
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety of ziprasidone and risperidone for the
treatment of chronic schizophrenia. The primary purpose is to differentiate the effects of
ziprasidone and risperidone on extrapyramidal side effects and the secondary purpose is to
compare their tolerability and efficacy.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.